摘要
目的 分析克拉霉素联合噻托溴铵治疗慢性阻塞性肺疾病 (COPD) 的临床效果。 方法 60 例慢性阻塞性肺疾病患者 , 按随机数字表法分为对照组和观察组 , 每组 30 例。对照组患者给予噻托溴铵治疗 , 观察组在对照组基础上增加克拉霉素治疗。比较两组患者治疗效果及治疗前后动脉血气指标[血氧分压 (PaO_(2))、二氧化碳分压 (PaCO_(2))]、肺功能指标[用力肺活量 (FVC)、第 1 秒用力呼气容积 (FEV1)]、炎性指标[肿瘤坏死因子 -α(TNF-α)、超敏 C 反应蛋白 (hs-CRP)、白细胞介素 -6(IL-6)]。结果 治疗前 , 两组 PaO2、PaCO_(2)及 FVC、FEV1 比较 , 差异无统计学意义 (P>0.05);治疗后 , 两组PaO2、PaCO_(2)及 FVC、FEV1 均优于治疗前 , 且观察组 PaO2(84.81±7.51)mm Hg(1 mm Hg=0.133 kPa)、PaCO_(2)(31.44±3.21)mm Hg 及 FVC(3.74±1.31)L、FEV1(3.52±0.34)L 优于对照组的 (76.42±6.34)mm Hg、(34.35±4.21)mm Hg、(2.45±1.11)L、(2.45±0.24)L, 差异有统计学意义 (P<0.05)。治疗前 , 两组 TNF-α、hs-CRP、IL-6 水平比较 , 差异无统计学意义 (P>0.05);治疗后 , 两组 TNF-α、hs-CRP、IL-6 水平均低于治疗前 , 且观察组 TNF-α(1.56±0.20)ng/ml、hs-CRP(7.19±1.12)mg/L、IL-6(61.56±2.16)pg/ml 低于对照组的 (2.41±0.28)ng/ml、(9.21±1.56)mg/L、(121.45±2.11)pg/ml, 差异有统计学意义 (P<0.05)。观察组总有效率 100.00% 高于对照组的 73.33%, 差异有统计学意义 (P<0.05)。结论 克拉霉素联合噻托溴铵治疗慢性阻塞性肺疾病效果显著 , 可有效改善动脉血气指标和肺功能指标 , 控制肺部炎性反应 , 值得推广。
Objective To analyze the clinical effect of clarithromycin combined with tiotropium bromide in the treatment of patients with chronic obstructive pulmonary disease (COPD). Methods A total of60 patients with chronic obstructive pulmonary disease were divided into control group and observation group according to the random numerical table, with 30 cases in each group. Patients in the control group were treated with tiotropium bromide, and patients in the observation group was treated with clarithromycin on the basis of the control group. Both groups were compared in terms of therapeutic effect, arterial blood gas indexes [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)], pulmonary function indexes[force vital capacity (FVC), forced expiratory volume in one second (FEV1)], inflammatory indexes [tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)] before and after treatment. Results Before treatment, there was no statistically significant difference in PaO2, PaCO2, FVC,and FEV1 between the two groups (P>0.05). After treatment, the PaO2, PaCO2, FVC, and FEV1 in both groups were better than those before treatment in this group;the observation group had PaO2of (84.81±7.51) mm Hg(1 mm Hg=0.133 kPa), PaCO2of (31.44±3.21) mm Hg, FVC of (3.74±1.31) L, and FEV1 of (3.52±0.34) L,which were better than (76.42±6.34) mm Hg, (34.35±4.21) mm Hg, (2.45±1.11) L, and (2.45±0.24) L in the control group;the differences were statistically significant (P<0.05). Before treatment, there was no statistically significant difference in the levels of TNF-α, hs-CRP and IL-6 between the two groups (P>0.05). After treatment,the levels of TNF-α, hs-CRP and IL-6 in both groups were lower than those before treatment in this group;the TNF-α (1.56±0.20) ng/ml, hs-CRP (7.19±1.12) mg/L and IL-6 (61.56±2.16) pg/ml in the observation group were lower than (2.41±0.28) ng/ml, (9.21±1.56) mg/L and (121.45±2.11) pg/ml in the control group;the differences were statistically significant (P<0.05). The total effective rate 100.00% in the observation group was higher than 73.33% in the control group, and the difference was statistically significant (P<0.05). Conclusion The effect of tiotropium bromide combined with clarithromycin in the treatment of chronic obstructive pulmonary disease is beneficial to improve arterial blood gas indicators and pulmonary function, and can effectively control pulmonary inflammatory indicators, which is worthy of promotion.
作者
于桐
YU Tong(Fuxin Mine General Hospital of Fuxin Liaojian Group,Fuxin 123000,China)
出处
《中国现代药物应用》
2023年第3期111-113,共3页
Chinese Journal of Modern Drug Application
关键词
克拉霉素
噻托溴铵
慢性阻塞性肺疾病
肺功能
Clarithromycin
Tiotropium bromide
Chronic obstructive pulmonary disease
Pulmonary function
